The high density of the extracellular matrix in solid tumors is an important obstacle to nanocarriers for reaching deep tumor regions and has severely limited the efficacy of administrated nanotherapeutics. The use of proteolytic enzymes prior to nanoparticle administration or directly attached to the nanocarrier surface has been proposed to enhance their penetration, but the low in vivo stability of these macromolecules compromises their efficacy and strongly limits their application. Herein, we have designed a multifunctional nanocarrier able to transport cytotoxic drugs to deep areas of solid tumors and once there, to be engulfed by tumoral cells causing their destruction. This system is based on mesoporous silica nanocarriers encapsulated within supported lipid bilayers (SLB). The SLB avoids premature release of the housed drug while providing high colloidal stability and an easy to functionalize surface. The tumor penetration property is provided by attachment of engineered polymeric nanocapsules that transport and controllably unveil and release the proteolytic enzymes that in turn digest the extracellular matrix, facilitating the nanocarrier diffusion through the matrix. Additionally, targeting properties were endowed by conjugating an antibody specific to the investigated tumoral cells to enhance binding, internalization, and drug delivery. This multifunctional design improves the therapeutic efficacy of the transported drug as a consequence of its more homogeneous distribution throughout the tumoral tissue.
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INTRODUCTION
Despite huge research efforts carried out in the last decades, cancer continues to be one of the leading causes of mortality worldwide. 1 Cancer cannot be considered as one simple disease.
There are many different types of cancer depending on the type of malignant cell and the affected organ and even patient specific heterogeneity. Therefore, each of them presents its own set of particular features and therapeutic challenges. Moreover, even within the same tumor type, usually coexists in multiple tumor clonal cell populations with different genetic alterations which respond differently to the common administered therapeutic agents. 2 When it is not possible to remove the tumoral mass by surgery, the common treatment involves the administration of high energy radiation (radiotherapy) and/or the use of potent cytotoxic compounds (chemotherapy) in order to destroy dividing cells. However, the lack of selectivity of these therapies causes severe systemic toxicity on surrounding healthy tissues compromising not only the efficacy of the therapy but also the patient´s life or quality of life. Since Maeda and Matsumura´s discovery in 1986 of passive accumulation of nanoparticles within tumoral masses, 3 the use of nanoparticles as drug carriers has been extensively studied in oncology. 4 This phenomenon, referred to as the
Enhanced Permeation and Retention effect (EPR), is caused by the unique blood vessel
architecture present in solid tumors that presents pores with diameters up to a few hundred nanometers. 5 Thus, when nanoparticles reach the tumoral area, they are extravasated into the tumor passing through these pores, whereas they cannot cross the healthy blood vessel walls. The discovery of the EPR effect triggered the development of a multitude of nanocarriers with the aim to deliver the cytotoxic compounds directly to the diseased zone, without affecting the rest of the healthy tissues. 6 These nanodevices have been engineered to possess remarkable 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   4 properties such as stimuli-responsive drug release, 7 invisibility to the immune system, 8 capacity to recognize the tumoral cells 9 or even target to the tumor stem cells. 10 However, the clinical application of nanocarriers is still far from being a reality. A recent meta-study concluded that only 0.7% of the administered nanoparticles accumulate in the tumoral tissue which could explain the low effectiveness of the nanotherapies observed in clinical trials. 11 One common problem in nanomedicine, is the lack of system penetration into the tumoral tissue. 12 The extracellular matrix of tumoral tissues has usually a denser extracellular matrix than their healthy counterparts due to the higher presence of collagen which limits the penetration of carriers into the tissue.. 13 Thus, the extravasated nanomedicine accumulates mainly on the periphery of the tumor where it can be easily flushed out of the tumor by intravasation after causing only local peripheral effects. The intratumoral administration of proteolytic enzymes such as collagenase or hyaluronidase prior to nanoparticle injection has been proposed to enhance the particle penetration. 14 These proteolytic enzymes have also been anchored on the nanocarrier surface resulting in improved particle penetration. 15 Recently, Villegas et al. reported the use of pHresponsive polymeric nanocapsules which contains collagenase for enhancing the particle penetration in 3D tumoral tissue models while protecting the proteolytic enzyme. 16 These nanocapsules were rapidly hydrolyzed under mild acidic conditions expected within hypoxic tumor tissue. In the mild acidic environment, the housed enzymes are released in two hours, whereas nanocapsule hydrolysis requires longer times under normal physiological conditions. In addition to achieving higher penetration within the tumoral mass, an efficient nanocarrier should be able to fulfill other features such as the ability to selectively bind to the target tumoral cell within a myriad of different cell populations and retain the transported therapeutic payload until it reaches the intracellular space of the malignant cell. Chemistry of Materials   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 5 Herein, we report the synthesis and evaluation of a novel multifunctional nanocarrier able to penetrate deeply within a solid tumoral mass while retaining their payload and selectively bind and internalize into tumor cells where the triggered release of the cytotoxic cargo leads to destruction of the targeted tumor cell. This nanodevice is composed of a mesoporous silica nanoparticle (MSN) capable of loading high amounts of drugs due to its very high specific area and accessible interior pore volume. The MSN external surface is encapsulated within a supported lipid bilayer conjugated with proteolytic NPs, targeting ligands, and PEG in a nanocarrier construct referred to as a protocell.
18,19
The protocell SLB serves to protect and retain cargo within the MSN until pH triggered release within acidified endosomal environments. 19 It also confers unique properties to the system such as high colloidal stability, low immunogenicity and long circulation times within the blood stream. The SLB of the protocell was decorated with pH-responsive collagenase nanocapsules for enhancing tissue penetration and with EGFR-antibodies, able to selectively bind to cells that overexpress epidermal growth factor receptors (EGFR), in order to increase the internalization of the protocell into tumoral cells and ensuing drug delivery. The capacity of this novel multifunctional protocell to recognize EGFR-positive tumoral cells which are deeply located within a solid tumoral mass was tested employing an in vitro 3D cell culture model, showing significantly improved penetration, internalization and destruction capacity of the malignant cells relative to protocells prepared without collagenase nanocapsules.
RESULTS

Synthesis of Protocells
The protocell MSN core was designed with hexagonally arranged cylindrical pores of diameter 3-4-nm, which represents the optimal size for loading therapeutic agents based on small 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 6 molecules, 20, 21 as is the case for many conventional cytotoxic compounds employed in antitumoral chemotherapy. 22 MSNs were synthesized following a modified Stöber method reported elsewhere, 23 yielding monodisperse nanoparticles with an average diameter of 75-100 nm according to dynamic light scattering (DLS) measurements ( Figure S1 ) and transmission electron microscopy (TEM) (Figure 1a ). MSNs were covalently labeled with rhodamine B throughout the silica matrix to enable fluorescence imaging. Figure S2 as an example). The presence of the lipid bilayer on the MSN surface was confirmed by TEM using phosphotungstic acid (PTA) as a staining agent (Figure 1b) . 26 The thickness of the supported lipid bilayer was measured to be ~4.7 nm on both batches (n = 20), which is in agreement with the values reported in the literature for 'protocell' systems. As was mentioned in the introduction, tumor penetration is one of the most important challenges facing the field of nanomedicine. The diffusion of nanometric objects in a fluid is understood by the Stokes-Einstein equation (D = KT/6πηr) which indicates that the diffusion rate (D) is inversely proportional to the particle radius (r) and also to the viscosity of the media (η).
Synthesis of Collagenase Nanocapsules (Col nc )
Therefore, the diffusion of nanometric objects is clearly reduced by increasing particle size and the viscosity of the media. Many solid tumors exhibit overproduction of collagen, which accumulates within the extracellular matrix (ECM) and greatly impedes particle diffusion through the inner tumoral core. The intratumoral injection of proteolytic enzymes able to destroy these collagen accumulations partially alleviates this problem, but due to the labile nature of these enzymes, it is necessary to administer several dosages of them in order to achieve significant results. Our research group has reported the use of polymeric nanocapsules which contain enzymes encapsulated within an organic shell in order to preserve their catalytic function in the presence of aggressive agents such as temperature or other proteolytic enzymes. 27, 28 Recently, collagenase has been encapsulated within pH-sensitive polymeric nanocapsules which were designed to rapidly release the housed enzyme when the pH drops to the mild acidic conditions usually present in many tumoral tissues but retains the enzyme trapped within the polymeric matrix up to 24 hours under normal physiological conditions. 16 Following the same methodology, collagenase polymeric nanocapsules were formed by a radical polymerization method which employs acrylamide (AA), as the main structural monomer, 2-aminoethylmethacrylate (Am) as the monomer that provides amino groups required for the further attachment on the protocell surface, and ethylenglycol dimethacrylate (EG) as pHdegradable cross-linker (Scheme 2). In this process, monomer/protein molar ratio of 2419:1 and AA:Am:EG ratio (7:6:2) were employed. The resulting nanocapsules were characterized by DLS measurements and TEM showing an average diameter of about 50 nm and a round-shaped morphology (Figure 1c) . The employed polymer composition was selected in order to exhibit degradation by progressive hydrolysis over 24 hours, which is accelerated in the mild-acidic conditions present in the tumor environment.
The nanocapsule degradation at physiological pH was monitored by following decrease in hydrodynamic diameter over time. We observed that the collagenase nanocapsules initially of ~50-nm in hydrodynamic diameter, were progressively degraded until they reached a size of ~7 nm, indicating the enzymes complete release after 24 hours ( Figure S4 ). The encapsulated collagenase retained its catalytic activity as was previously reported. 16 
Protocell functionalization: Anchoring of anti-EGFR and collagenase nanocapsules.
In order to confer selectivity against tumoral cells, the nanoparticle surface was decorated with 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 11 Scheme 2. Synthesis of Col nc (upper scheme) and attachment pathway of Col nc and Anti-EGFRbiotin on PC surface (lower scheme). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   12 The first step (i) was the conversion of the amino groups present on the protocell surface into thiol groups by the reaction with 2-iminothiolane hydrochloride (Traut's reagent). Then, these thiol groups were employed to anchor the maleimide-neutravidin moieties (ii). Thus, the protocells were ready for the antibody introduction employing biotinylated-Anti-EGFR (iv or v).
Due to the sensitive nature of antibodies, collagenase nanocapsules were anchored (iii) prior to the introduction of antibody in order to preserve the recognition capacity of this macromolecule.
As was mentioned above, two protocell batches displaying different percentages of carboxylic groups were synthesized (PC-COOH13 and PC-COOH30) in order to find the optimal composition which resulted in a higher collagenase nanocapsule attachment. Thus, collagenase nanocapsules were anchored on both types of protocells, using well-known carbodiimide chemistry (iii). The presence of collagenase nanocapsules was confirmed by measuring the enzymatic activity of the PC-COOH13-Col nc and PC-COOH30-Col nc respectively, using EnChekGelatinase/Collagenase Assay Kit. Both samples exhibited similar enzymatic activity and therefore, an increase in the amount of carboxylic groups on the PC surface did not improve the Col nc attachment ( Figure S5) . Additionally, the colloidal stability of PC-COOH13-Col nc was significantly higher than PC-COOH30-Col nc, showing that the particles remained well suspended in PBS for more than 15 days. For these reasons, PC-COOH13-Col nc was selected as the best system for the further attachment of Anti-EGFR which was carried out through the formation of a biotin-neutravidin bridge (iv and v).
In vitro Evaluation of Protocell targeting capacity in 2D model
As described above, Anti-EGFR was anchored on the protocell surface for improving the particle uptake within the tumoral cells. The capacity of these systems to selectively bind to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 whereas this value rose to over 90% when the antibody was present. In the complete system (Col nc -PC-Anti-EGFR), collagenase nanocapsules were anchored prior to the antibody functionalization. This anchoring process requires carboxylic acid activation by carbodiimide chemistry, which could alter the neutravidin pockets due to the presence of carboxylic and amine groups in this protein and therefore could compromise the antibody conjugation. In order to evaluate this possibility, the cells were exposed to Col nc -PC-Anti-EGFR and compared to the PC-Anti-EGFR alone. Both the full construct, Col nc -PC-Anti-EGFR, and PC-Anti-EGFR yielded similar uptake of 85% and >90% respectively, confirming the suitability of this strategy for the synthesis of the complete nanodevice.
Evaluation of penetration capacity in 3D tumoral tissue model
In order to evaluate the penetration capacity of these multifunctional protocells, a 3D tissue 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 engulfed within the cell cytoplasm thanks to the presence of the targeting moiety, actin filaments were stained with green phalloidin. The confocal images show that only protocells functionalized with nanocapsules were able to reach the bottom layer, as can be observed by the existence of perinuclear red dots which correspond to the rhodamine B labeled MSN cores of the protocells.
This result confirms the capacity of Col nc -PC-Anti-EGFR to overcome the collagen barrier and reach deep layers of the tissue model. In addition, these protocells were found within the tumoral cell cytosol, which confirms the enhanced internalization of these nanocapsule-bearing protocells inside malignant cells. On the contrary, PC-Anti-EGFR were not able to overcome the collagen barrier and they were likely removed in the washing step, as can be observed by the absence of red dots (labeled nanocapsule-free protocells) in the cell layer.
Evaluation of cytotoxic capacity of drug-loaded protocells in 3D tumoral tissue model
Having established the ability of Col nc -PC-Anti-EGFR to reach deep areas within a 3D tumoral model and once there, to be selectively internalized by tumoral cells, the ability of the system to transport and deliver cytotoxic drugs capable of inducing cell death was studied. Topotecan (TOP) is a potent antitumoral therapeutic but it suffers significant instability in the blood stream losing its activity in a few hours. 33 For this reason, repeated dosages are required in order to maintain its concentration in the blood, which leads to severe side effects. It has been reported that the encapsulation of TOP within a nanocarrier improves its therapeutic efficacy. 34 For these reasons, topotecan was selected as drug model for this system. Col nc -PC-Anti-EGFR were loaded prior to the formation of the protocell by incubating the silica core for 24 hours in an aqueous solution of topotecan (3 mg·mL -1 ). The loading capacity of the protocells was determined by differences in fluorescence between the topotecan solution, before and after the loading, yielding topotecan-loaded Col nc -PC-Anti-EGFR induced around 40% of cell mortality, whereas the system which did not contain the collagenase nanocapsules had negligible cytotoxicity ( Figure   4 ). After 48 hours, the cytotoxicity observed in the case of topotecan(TOP)-loaded Colnc-PCAnti-EGFR reached up to 60% and PC-Anti-EGFR induced around 20% of cell destruction. The cytotoxicity provoked by this last nanodevice was probably caused by the small amount of TOP that leaks from protocells when they are exposed to physiological conditions over a relatively long timespan ( Figure S7 ). 18 These results confirmed that the higher penetration capacity of collagenase nanocapsules results in significant improvements in the therapeutic efficacy of the cytotoxic compounds transported by these multifunctional protocells. 
Conclusions
Herein, a multifunctional tumor-penetrating nanocarrier capable of selective delivery of antitumoral drugs to deep tumoral layers has been developed. This system is composed of mesoporous silica nanocarriers encapsulated within a supported lipid bilayer (aka protocell). The SLB of the protocell construct was modified with collagenase containing nanocapsules that serve to digest the highly dense tumoral extracellular matrix and enable protocell penetration. These collagenase nanocapsules were designed to protect the enzymatic activity of the collagenase until the target tissue is reached and then, to have pH-triggered (accelerated) release of collagenase within the tumoral area. Additionally, the "plug and play" feature of protocell surface allowed anchoring of EGFR antibodies, whose receptors are commonly overexpressed in human lung cancer cells, allowing a preferential internalization within tumoral cells. Thus, the system achieves highly efficient penetration within dense matrix, selective internalization by tumoral cells and successful and controlled delivery of cytotoxic anticancer drugs. The importance of this system was highlighted by employing a 3D tumoral tissue model that mimics the extracellular matrix present in diseased tissues. Therefore, this system has demonstrated the capability to overcome one of the major problems of current nanomedicine, which is the limited penetration of nanosystems. The application of this strategy would pave the way for the design of smarter nanoconstructs able to achieve more homogeneous drug distribution within solid tumors, which is an important advance toward their clinical applications.
MATERIALS AND METHODS
Materials
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Instrumental section
The hydrodynamic size of mesoporous nanoparticles and protein capsules was measured by means of a Zetasizer Nano ZS (Malvern Instruments) equipped with a 633 nm "red" laser.
Transmission Electron Microscopy (TEM) was carried out with a JEOL TEM 3000 instruments 
Synthesis of Mesoporous Silica Nanoparticles (MSN)
In order to prepare dye-labeled mesoporous silica nanoparticles, 1. • C under magnetic stirring for 1 h without parafilm, then the solution was aged at 50 • C overnight under static conditions. The next day, the particles were subjected to a hydrothermal treatment at 70°C for 20 h before being collected by centrifugation and washed three times with water and ethanol. The surfactant was removed placing the particles in 500 mL of a solution of 95% ethanol, 5% water, and 10 g NH 4 NO 3 mL −1 at 80 °C during 3 h with reflux and under stirring.
The nanoparticles were washed with ethanol and were finally stored in pure ethanol.
Liposome preparation
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times. Then monodispersed liposomes were obtained.
Synthesis of Protocells (PC-CO 2 H13 and PC-CO 2 H30)
The silica nanoparticles were transferred to water at (2.5 mg/mL) from the ethanolic suspension by centrifugation (15000 rpm, 10 min) and resuspension in water. To each batch of MSN, a suspension of liposomes 8ˑ10 -6 mol in 1.2 mL of PBS with 13% or 30% of carboxylic groups was added. The mixtures were sonicated for 20 s and the excess of liposomes was removed by centrifugation (15000 rpm, 10 min). The pelleted protocells were redispersed in PBS(1x) by sonication; this process was repeated two times. Finally, the protocells were stored in 1 mL of PBS (2.5 mg/mL). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 22 deoxygenated buffer were added. The solution was stirred at 300 rpm for 90 min at room temperature under inert atmosphere. Next, the encapsulated enzyme was purified by centrifugal separation with 10 KDa cut-off filters (AMICON Ultra-2 mL 10 KDa) and washed three times with NaHCO 3 buffer (0.01 M pH 8.5). The capsules of collagenase were preserved at 4 °C.
Synthesis of Collagenase Capsule (Col nc
)
Protocells functionalization with Anti-EGFR and Col nc
Conversion of NH 2 groups into SH groups, 125 µL of 250 mM Traut´s reagent in PBS was
added to the protocells. The reaction was kept for 2 h under stirring at room temperature. After this time, the excess of Traut´s reagent was removed via centrifugation (15000 rpm, 10 min) and the pellet of protocells was resuspended in PBS. This step was repeated twice. Finally, the thiolfunctionalized protocells were stored in 1 mL of PBS (2.5 mg·mL -1 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 NeutrAvidin were collected by centrifugation and washed three times with PBS. Col nc -PCNeutrAvidin were stored at 4 °C. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   24 24 h. Then, the collagen gel with A549 cells embedded into the collagen matrix was directly prepared in contact with the cell monolayer. For this purpose, 5.32 mL of rat tail collagen type I (3 mg·mL -1 ) and 15.48 mL of complete medium (Dulbecco's modified eagle's medium complemented with 10% of FBS) were mixed at 0 °C. Then, 100 µL of sodium hydroxide were added in order to obtain a mixture with neutral pH. 5 mL of FBS, 5 mL of complete medium and 5 mL of a solution of cells of concentration A549 1.7 × 10 6 cell·mL -1 were added to the neutral collagen solution, keeping the temperature at 0 °C. The mixture was pipetted into 24 well plates (0.25 mL per well) and incubated at 37 °C at 5% CO 2 atmospheric concentration for 1 day, in order to promote gel formation. Then, 250 µL of complete medium was added in each well and the gel was incubated at 37 °C at 5% CO 2 atmospheric concentration overnight. These gels were used for the further experiments 2 days after gel formation.
Attachment of
Synthesis of Col nc -PC-Anti-EGFR
Study of penetration and cell internalization in A549-seeded collagen gels.
To study the penetration of nanocarriers in 3D tumoral tissue models, 80 µL of suspended PC-Anti-EGFR and
Col nc -PC-Anti-EGFR (1 mg·mL −1 ) were respectively added on top of each gel. These samples were incubated at 37 °C at 5% CO 2 atmospheric concentration during 24h. Then, the supernatant was removed and the gel was washed twice with PBS. Then, 0.5 mL of a solution 4%
paraformaldehyde and 1% sucrose in PBS was added to each well, and were incubated for 20min. After this time, the wells were washed two times with PBS 1x and 0.5 mL of a solution of 0.5% triton X-100 in PBS was added and the wells were incubated during 5 min at room temperature in order to permeate the cell membrane. Then, the wells were washed with PBS and incubated for 20 min at 37 ºC with a solution of BSA 1% in PBS. After this step, BSA was removed and 0.5 mL of a solution of 30 µL of ATTO488 phallloidine solution (1 mg·ml -1 in methanol) in 1 mL of BSA1%, was added. The wells were incubated for 40 min, and washed two 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 25 times with PBS(1x). Then, 0.5 mL of one solution of DAPI in PBS (0.1µg/mL) was added and the wells were incubated during15 min at room temperature. Finally, the excess of DAPI was removed washing two times with PBS(1x). The samples were ready for observation by fluorescent confocal microscopy.
Topotecan loading
1 mL of ethanolic suspension of MSN (2.5 mg·ml -1 ) was washed two times with water and finally was resupended in 0.5 ml of an aqueous solution of topotecan (5 mg·ml -1 ) during 12
hours. The excess of topotecan was removed by centrifugation (15000 rpm, 10 min) and two washing steps in H 2 O. The amount of topotecan housed in MSN was determined by the difference in fluorescence in the initial cargo solution and the resulting supernatant. These topotecan-loaded MSN were employed for the drug-loaded protocell following the method described above.
Cell Viability Studies.
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ASSOCIATED CONTENT
Multifunctional protocell capable to penetrate deep into 3D extracellular matrices and once there, recognize and destroy tumoral cells.
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ACS Paragon Plus Environment
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